𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Double-blind placebo-controlled house dust mite control measures in adult patients with atopic dermatitis

✍ Scribed by C. Gutgesell; S. Heise; S. Seubert; A. Seubert; S. Domhof; E. Brunner; C. Neumann

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
400 KB
Volume
145
Category
Article
ISSN
0007-0963

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Azathioprine in severe adult atopic derm
Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial
✍ J. Berth-Jones; A. Takwale; E. Tan; G. Barclay; S. Agarwal; I. Ahmed; K. Hotchki 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 160 KB

## Background: There is a limited range of treatments for severe atopic dermatitis (ad). azathioprine has often been used but there has been no randomized controlled trial of this drug to confirm its efficacy in ad. ## Objectives: To establish or refute the efficacy of azathioprine in severe ad.

Effects of nitrazepam on nocturnal scrat
Effects of nitrazepam on nocturnal scratching in adults with atopic dermatitis: a double-blind placebo-controlled crossover study
✍ Ebata; Izumi; Aizawa; Kamide; Niimura 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 314 KB

We investigated the effect of nitrazepam on nocturnal scratching in 10 adult out-patients with atopic dermatitis (AD) using a double-blind placebo-controlled crossover method. Patients were given either nitrazepam (Benzalin tablets containing 5 mg nitrazepam) or a placebo on 3 successive nights, wit

European/Canadian multicenter, double-bl
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis
✍ Giancarlo Comi; Massimo Filippi; Jerry S. Wolinsky 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 698 KB

## Abstract Two prior double‐blind, placebo‐controlled, randomized trials demonstrated that glatiramer acetate (GA) reduces relapse rates in patients with relapsing remitting multiple sclerosis (RRMS). This study was designed to determine the effect, onset, and durability of any effect of GA on dis